Bristol-Myers Squibb BMY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.27B+3.1% | $7.06B+18.2% | $5.97B+19.6% | $4.99B-6.9% | $5.36B+160% | ||
| $3.59B-10.4% | $4.01B-18.4% | $4.91B-24.3% | $6.5B-19.6% | $8.08B-15.8% | ||
| $555M+0.4% | $553M+2.4% | $540M+1.9% | $530M+2.3% | $518M+2.2% | ||
| -$1.03B-6.4% | -$965M+29.3% | -$1.36B-8.2% | -$1.26B-9.2% | -$1.16B+44.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $129M+3,325% | -$4M-101% | $320M+135% | -$915M+59.1% | -$2.24B-62.0% | ||
| —— | —— | —— | -$335M-268% | $200M+176% | ||
| $13.31B-6.0% | $14.16B-14.8% | $16.62B+4.5% | $15.9B+11.1% | $14.31B-5.8% | ||
| $1.4B+6.6% | $1.31B-0.6% | $1.32B-0.3% | $1.32B+8.1% | $1.22B-1.9% | ||
| $3.93B-0.3% | $3.94B+72.7% | $2.28B+201% | $758M-58.9% | $1.85B-91.5% | ||
| -$3.76B+8.9% | -$4.13B-44.0% | -$2.87B-107% | -$1.39B+37.9% | -$2.23B+89.5% | ||
| $5.07B+0.5% | $5.05B+0.9% | $5B+0.9% | $4.95B+0.9% | $4.91B+0.9% | ||
| $11.44B+4.6% | $10.94B+1,155% | $872M-72.1% | $3.12B+8.6% | $2.87B0.0% | ||
| -$10.92B-5.5% | -$10.35B— | —— | —— | —— | ||
| $85M-57.3% | $199M+323% | $47M-62.1% | $124M+577% | -$26M+81.0% | ||
| -$1.29B-902% | -$129M— | —— | —— | —— | ||
| $3.63B-2.5% | $3.72B+57.8% | $2.36B+18.7% | $1.99B+225% | $612M-95.4% | ||
| —— | $351M+4.5% | $336M0.0% | $336M— | $0— | ||
| —— | —— | —— | —— | $1.13B+1.1% | ||
| $1.51B+37.1% | $1.1B-55.5% | $2.47B+2.4% | $2.41B-18.8% | $2.97B+0.1% | ||
| -$3.31B-650% | -$441M— | —— | —— | —— | ||
| -$248M-6.9% | -$232M— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.07B-2.9% | ||
| $2.11B+7.0% | $1.98B+20.8% | $1.64B+56.6% | $1.04B+75.5% | $595M-47.0% | ||
| $456M+492% | $77M-71.1% | $266M+22.6% | $217M-20.2% | $272M+2.6% | ||
| -$134M+3.6% | -$139M-11.2% | -$125M— | —— | —— | ||
| —— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $11.91B-7.3% | $12.85B-16.1% | $15.3B+5.0% | $14.58B+11.4% | $13.09B-6.1% | ||
| $11.91B-7.3% | $12.85B-16.1% | $15.3B+5.0% | $14.58B+11.4% | $13.09B-6.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bristol-Myers Squibb generate?
- Bristol-Myers Squibb (BMY) generated $13.3B in operating cash flow over the trailing twelve months.
- What is Bristol-Myers Squibb's free cash flow?
- After $1.4B of capital expenditures, Bristol-Myers Squibb's free cash flow was $11.9B over the trailing twelve months, down 9.0% year over year.
- Where does Bristol-Myers Squibb's cash flow data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
